Sihuan Pharmaceutical (00460) appoints Che Yuxuan as a non-executive director, and the two-wheel drive strategy has doubled profits in the medium term

Zhitong Finance App learned that Sihuan Pharmaceutical (00460) recently underwent an optimization and upgrade of its governance structure and announced the appointment of Mr. Che Yuxuan as a non-executive director of the company and a member of the Board Risk Management Committee, effective August 26, 2026. With its international research background and diverse perspectives, the addition of a new non-executive director is expected to inject new momentum into the company's commercialization of innovative drug pipelines and the empowerment of AI research and development.

According to the announcement, Mr. Che Yuxuan has a bachelor's degree in biology from the University of Washington, worked as a data scientist at the Massachusetts General Hospital, and worked in marketing and sales at Sanofi Pasteur. It is worth noting that Mr. Che Yuxuan has been deeply involved in the biomedical field for a long time. He has a combined history of first-line scientific research, commercialization of multinational pharmaceutical companies, and strategic management of innovative pharmaceutical companies. He has a deep understanding of innovative drug R&D, clinical promotion, and commercialization implementation, and has accumulated rich experience in the industry. Market analysts believe that its professional accumulation in the biomedical industry is highly compatible with Sihuan Pharmaceutical's current “medical aesthetic+innovative drug” two-wheel drive strategy. Entering the board of directors this time will help strengthen the company's ability to make strategic decisions and integrate resources in the innovative drug sector, which is beneficial to the company's long-term development.

In terms of performance, Sihuan Pharmaceutical recently announced its 2026 interim results. The group achieved total revenue of 1,161 billion yuan during the period, an increase of 1.3% over the previous year; the company's owners should account for profit of 225 million yuan, an increase of 119% over the previous year. Revenue growth was mainly driven by the medical aesthetic and innovative drug business. Among them, the revenue from the medical and aesthetic business was about 693 million yuan, up about 18.5% year on year. The steady growth of the core product Lotivo® (botulinum toxin), as well as the continued release of regenerative medical and aesthetic products (including beauty acupuncture and teenage acupuncture) and functional medical and aesthetic products, are driving the revenue growth of the medical and aesthetic related business.

Revenue from innovative drugs and other pharmaceuticals was approximately 261 million yuan, up about 349.1% year over year. The commercialization process of the innovative drug business continues to advance. The commercialization and internationalization of various approved products progressed well, and consolidated revenue ushered in a significant increase. Compared with the net loss of the previous period, net profit for the current period increased slightly.